| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2012 | US20120021036 Composite nanostructures and methods for making and using them |
| 01/26/2012 | US20120021035 Nanoparticles containing plymeric nucleic acid homologs, pharmaceutical composition and articles of manufacture containing same and methods of use thereof |
| 01/26/2012 | US20120021021 Method for preparing pharmaceutical compositions comprising fine particles of active substance |
| 01/26/2012 | US20120021020 Branched amphipathic oligo-peptides that self-assemble into vesicles |
| 01/26/2012 | US20120021017 N-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120021016 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/26/2012 | US20120021015 Crosslinked fibers and method of making same using uv radiation |
| 01/26/2012 | US20120021013 Composition Containing Sulfoalkyl Ether Cyclodextrin and Latanoprost |
| 01/26/2012 | US20120021010 Antiplatelet agent and methods of using the same |
| 01/26/2012 | US20120021009 Process for making gastroretentive dosage forms |
| 01/26/2012 | US20120021007 Nitric oxide furoxan derivative compounds endowed with antitumoral activity |
| 01/26/2012 | US20120021000 HIV DNA Vaccine Methods of Use |
| 01/26/2012 | US20120020977 Pancreatic cancer genes |
| 01/26/2012 | US20120020967 VEGF antibodies comprising modular recognition domains |
| 01/26/2012 | US20120020966 Multispecific antibody targeting and multivalency through modular recognition domains |
| 01/26/2012 | US20120020959 Use of the sparc microenvironment signature in the treatment of cancer |
| 01/26/2012 | US20120020958 Fibcd1 for the prevention and treatment of diseases |
| 01/26/2012 | US20120020957 Dengue virus neutralizing antibodies and use thereof |
| 01/26/2012 | US20120020954 Methods of predicting clinical course and treating multiple sclerosis |
| 01/26/2012 | US20120020953 Diagnosis and treatment of cancer |
| 01/26/2012 | US20120020952 Methods for producing mixtures of antibodies |
| 01/26/2012 | US20120020951 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | US20120020950 Antibacterial compounds |
| 01/26/2012 | US20120020948 Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke |
| 01/26/2012 | US20120020945 Food Supplement and Method for Enhancing Athletic Performance |
| 01/26/2012 | US20120020940 Antimicrobial peptides |
| 01/26/2012 | US20120020923 Method of treating viral diseases with combinations of TPO receptor agonist and anti-viral agents |
| 01/26/2012 | US20120020922 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| 01/26/2012 | US20120020921 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| 01/26/2012 | US20120020920 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor |
| 01/26/2012 | US20120020915 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System |
| 01/26/2012 | US20120020902 Pharmaceutical, dermatological, nutritional or cosmetic composition for combating the immunosuppressive action of aggressive agents on the skin |
| 01/26/2012 | US20120020888 Biomarker |
| 01/26/2012 | US20120020886 Thermal spin cross-over compounds and methods of using same |
| 01/26/2012 | US20120020881 Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes |
| 01/26/2012 | US20120020877 Process and intra-cervical device for the local release of drugs in the local-regional treatment of cervical cancer |
| 01/26/2012 | US20120020876 Hedgehog pathway inhibitors |
| 01/26/2012 | US20120020833 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 01/26/2012 | US20120018334 Conjugated antimicrobial agents |
| 01/26/2012 | US20120018333 Reducing Side Effects of Tramadol |
| 01/26/2012 | US20120017924 Coated nicotine-containing chewing gum, manufacture and use thereof |
| 01/26/2012 | US20120017892 Use of salt of an acetylsalicylic acid for the treatment of viral infections |
| 01/26/2012 | DE102010031667A1 Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung Substituted methyl-pyrimidin-5-ylcarbamate and their use |
| 01/26/2012 | DE102010031666A1 Carbamat-substituierte Diaminopyrimidine und ihre Verwendung Carbamate substituted diaminopyrimidines and their use |
| 01/26/2012 | DE102010031665A1 Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung Substituted oxazolidinones and Oxazinanone and their use |
| 01/26/2012 | DE102010027595A1 Clinical application of adenosine derivative, preferably (dihydroxyphenyl)ethyl-amino-purin-9-yl-(hydroxymethyl)oxolane-diol, for reducing body temperature during impending ischemia of brain vessels, which occur during heart attacks |
| 01/26/2012 | CA2829046A1 Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| 01/26/2012 | CA2809405A1 Compounds for photodynamic therapy |
| 01/26/2012 | CA2808432A1 Tricyclic proteasome activity enhancing compounds |
| 01/26/2012 | CA2806476A1 Substituted indoles, antiviral active component, method for producing and using same |
| 01/26/2012 | CA2806362A1 Administration of rifalazil to immunocompromised patients |
| 01/26/2012 | CA2806271A1 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics |
| 01/26/2012 | CA2806260A1 Tacrolimus-containing oil-in-water type creamy composition |
| 01/26/2012 | CA2806258A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | CA2806256A1 Oral medicinal composition for patients undergoing peritoneal dialysis and method for using same |
| 01/26/2012 | CA2806232A1 Noribogaine compositions |
| 01/26/2012 | CA2806221A1 Tricyclic compounds and methds of making and using same |
| 01/26/2012 | CA2806108A1 2,3,5-trisubstituted thiophene compounds and uses thereof |
| 01/26/2012 | CA2806069A1 Methods of intravenous administration of glyburide and other drugs |
| 01/26/2012 | CA2806062A1 Topical treatment of neuropathic pain and methods of diagnosis |
| 01/26/2012 | CA2806058A1 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | CA2806051A1 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anticancer agent, method for producing and using same |
| 01/26/2012 | CA2806017A1 Methods of use of cyclic amide derivatives to treat schizophrenia |
| 01/26/2012 | CA2805991A1 Methods and compositions for inhibiting the nuclear factor kb pathway |
| 01/26/2012 | CA2805980A1 Combination of siloxane and active ingredient for treating dental disorder |
| 01/26/2012 | CA2805968A1 Pharmaceutical composition containing a tryptophan derivative |
| 01/26/2012 | CA2805959A1 Crystals of carboprost tromethamine and the preparation method as well as the uses thereof |
| 01/26/2012 | CA2805904A1 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| 01/26/2012 | CA2805874A1 Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 01/26/2012 | CA2805868A1 Process for preparing benzofuran derivatives substituted at position 5 |
| 01/26/2012 | CA2805824A1 Compositions comprising derivatives of essential oil compounds and use in personal care products |
| 01/26/2012 | CA2805808A1 Agonists of gpr40 |
| 01/26/2012 | CA2805791A1 Modulation of nuclear-retained rna |
| 01/26/2012 | CA2805774A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| 01/26/2012 | CA2805765A1 Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
| 01/26/2012 | CA2805745A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | CA2805693A1 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| 01/26/2012 | CA2805658A1 Combination therapy with mdm2 and efgr inhibitors |
| 01/26/2012 | CA2805612A1 Biodegradable nano-, meso- and micro-polymer particles for maintaining a low surface tension in the lung and for protecting the pulmonary surfactant |
| 01/26/2012 | CA2805567A1 Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them |
| 01/26/2012 | CA2805430A1 Method for preparing microspheres and microspheres produced thereby |
| 01/26/2012 | CA2805427A1 Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
| 01/26/2012 | CA2805319A1 Use of a fermented soy extract for manufacture of a prebiotic composition |
| 01/26/2012 | CA2805242A1 Bifunctional rho kinase inhibitor compounds, composition and use |
| 01/26/2012 | CA2805098A1 Pyridin-2-yl sulfanyl acid esters and process for the preparation thereof |
| 01/26/2012 | CA2804725A1 Pharmaceutical depot for 5- fluoro-2-[[(1s)-1-(5- fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile |
| 01/26/2012 | CA2804622A1 Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment |
| 01/26/2012 | CA2804110A1 Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| 01/26/2012 | CA2803467A1 New aminopyrazoloquinazolines |
| 01/26/2012 | CA2803368A1 Ophthalmic devices containing chemokine antagonists |
| 01/26/2012 | CA2803006A1 Methods and compositions for treatment of multiple sclerosis |
| 01/26/2012 | CA2803005A1 Synthesis and use of kinase inhibitors |
| 01/26/2012 | CA2801781A1 Protein kinase c inhibitors and uses thereof |
| 01/25/2012 | EP2410332A1 Method for identifying purinergic modulators of the olfactory system |
| 01/25/2012 | EP2410054A1 Antisense compounds |
| 01/25/2012 | EP2410031A1 Base material for spraying comprising low-molecular gelling agent |
| 01/25/2012 | EP2409984A1 Dimeric IAP Antagonists |
| 01/25/2012 | EP2409977A1 Amide derivative |
| 01/25/2012 | EP2409976A1 Glycine transporter inhibitor |
| 01/25/2012 | EP2409973A1 New crystal form and pharmaceutical compositions of (+)-R-zileuton |